 Historically, monoclonal antibodies, such as blockbuster drug, Humira®, have performed as the best-selling drugs in the world. Targeting across multi-indications such as autoimmune disorders and degenerative diseases, these drugs have multi-billion dollar blockbuster potential. But did you know, that to this day, no drug on the market is a fully human, anti-CD3 monoclonal antibody? This may change thanks to one little-known NASDAQ company that has a drug in clinical development that is the world's ONLY full human anti-CD3 monoclonal antibody! This company has the potential to revolutionize the way immunotherapies are currently conducted with its game-changing approach to attacking neurodegenerative diseases and lung diseases. The company's drug is a First-in-class asset that is gaining global recognition with articles featured in Forbes and Jama Network! Similar monoclonal antibody drugs, such as Humira®, have performed extraordinarily well with approximately 200 billion dollars in revenue. With three clinical trials across neurodegenerative, autoimmune, and lung disease indications, the company is attacking multiple indications and should be high on your radar! Discover how with an impressive team and board of scientists, this underfollowed company aims to disrupt biopharma with its potentially breakthrough therapies all while building shareholder value!This message is a PAID ADVERTISEMENT for Tiziana Life Sciences (NASDAQ: TLSA) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1500. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Tiziana Life Sciences (NASDAQ: TLSA) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Tiziana Life Sciences (NASDAQ: TLSA) on Small Caps Daily website for additional information about the relationship between Interactive Offers and Tiziana Life Sciences (NASDAQ: TLSA). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc |
Today's Bonus Content: BTC Wealth Event to Repeat on APRIL 22!
Post a Comment
Post a Comment